BioMarin Stock Surges on $275 Million Alesta Acquisition Deal

3-line summary

• BioMarin Pharmaceutical shares surged after the company announced a $275 million acquisition deal for Alesta, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.